1例弥漫大B细胞淋巴瘤伴快慢综合征患者R-CHOP方案化疗的药学监护分析

Analysis of Pharmaceutical Care of One Patient with Diffuse Large B Cell Lymphoma Combine Tachycardia-bradycardia Syndrome Undergoing R-CHOP Chemotherapy

关键词:  快慢综合征  R-CHOP  不良反应  药学监护

Key words:  tachycardia-bradycardia syndrome  R-CHOP  adverse reactions  pharmaceutical monitoring

摘要:

目的 探讨快慢综合征患者行R-CHOP方案化疗前综合处理方法及药学监护注意事项，保证患者化疗安全有效。方法 临床药师通过参与1例快慢综合征R-CHOP方案化疗药学监护，从快慢综合征化疗前的处理方法及各种不良反应预防措施等方面进行分析，并提供药学监护。结果 快慢综合征等心律失常患者，在行R-CHOP方案化疗时一定要先纠正心律，并在严格监护下进行化疗，并尽可能选择同类药物中心脏毒性较小的药物，密切监测不良反应的发生。结论 临床药师通过对该患者化疗过程进行药学监护分析与总结，为临床心功能不全且必须行R-CHOP方案化疗的淋巴瘤患者提供了用药指导，能有效避免不良反应的发生。

Abstract:

OBJECTIVE To explore the comprehensive treatment method of patients with tachycardia-bradycardia syndrome before using R-CHOP regimen chemotherapy and the precautions of pharmaceutical monitoring to ensure the safety and effeciency of chemotherapy. METHODS The clinical pharmacist participated in the R-CHOP regimen chemotherapy of a patient with tachycardia-bradycardia syndrome, analyzed from the aspects of treatment before chemotherapy and preventive measures for adverse reactions, and provided pharmaceutical care. RESULTS Patients with arrhythmia, such as tachycardia- bradycardia syndrome, must correct the heart rhythm while undergoing R-CHOP chemotherapy, and perform chemotherapy under strict supervision, and choose the drugs with less cardiac toxicity among the same drugs as possible, and closely monitor adverse reactions. CONCLUSION The clinical pharmacist conducts pharmacological monitoring of the patient's chemotherapy process, and comprehensively analyzes and summarizes the experience. It provides medication guidance for patients with lymphoma who have clinical cardiac insufficiency and must undergo R-CHOP chemotherapy.